The COVID-19 pandemic negatively impacted the amniotic products market growth, attributed to the reduced use of amniotic products due to the declining volume of elective and non-essential procedures, the lower diagnosis, reduced capital spending by customers, and a decrease in research activities due to laboratory closures and reduced clinical testing.